ZimVie reported net sales of $116.7 million for the second quarter of 2025, a slight decrease of 0.1% year-over-year. The company significantly improved its net loss, reducing it to $(3.8) million from $(9.6) million in the prior year, and achieved an adjusted diluted EPS of $0.26. Adjusted EBITDA also saw an increase to $17.5 million, reflecting improved operational efficiency.

ZimVie Inc. reported first quarter 2025 financial results with net sales of $112.0 million, a 5.2% decrease from the prior year. The company significantly improved its net loss, reducing it to $(2.6) million from $(11.5) million in the first quarter of 2024. Adjusted EBITDA also saw a substantial increase.

ZimVie reported fourth quarter 2024 net sales of $111.5 million, a 1.4% decrease from the previous year. Despite this, the company significantly improved its net loss, reducing it to $(9.7) million from $(22.2) million in Q4 2023, and saw an increase in adjusted EBITDA to $18.4 million.

ZimVie reported third-party net sales of $103.2 million, a decrease of 2.0% compared to the third quarter of 2023. The company's net loss was $(3.0) million, an improvement of $7.2 million year-over-year, with a GAAP diluted EPS of $(0.11) and an adjusted diluted EPS of $0.12.

ZimVie reported a slight decrease in third-party net sales but showed improvement in adjusted EBITDA and adjusted EPS. The company reaffirmed its full-year guidance for net sales, adjusted EBITDA, and adjusted EPS.

ZimVie reported a slight decrease in third-party net sales, a net loss of ($11.5) million, and an adjusted EBITDA of $12.5 million. The company completed the sale of its spine business and repaid a significant portion of its debt.

ZimVie's Q4 2023 results showed a mix of challenges and progress. The company reported a decrease in third-party net sales for both continuing (Dental) and discontinued (Spine) operations. However, adjusted net income increased for both segments. The company is advancing its plan to sell the Spine business and transform into a pure-play dental company.

ZimVie reported third-party net sales of $202.9 million, a decrease of 4.9% compared to the third quarter of 2022. The company experienced a net loss of $5.1 million, with a diluted EPS of ($0.19). Adjusted diluted EPS was $0.08. The company's cash and cash equivalents totaled $75.4 million as of September 30, 2023.

ZimVie reported third-party net sales of $224.9 million, a decrease of 3.6% compared to the second quarter of 2022. The company's net loss was $23.4 million, or ($0.89) per share, while adjusted diluted EPS was $0.17. Adjusted EBITDA was $29.7 million, representing 13.2% of third-party net sales.

ZimVie reported a decrease in third-party net sales by 4.1% to $225.1 million for Q1 2023. The company experienced a net loss of $30.0 million, or ($1.14) per diluted share. Adjusted diluted EPS was $0.25. The company is implementing restructuring activities to reduce costs and streamline operations.

ZimVie reported a decrease in third-party net sales for Q4 2022, driven by declines in both the dental and spine segments. The net loss decreased compared to the previous year, while adjusted net income increased. The company launched several innovative products and drove operational progress.

ZimVie reported third-party net sales of $213.3 million. Net income was $0.8 million, with a diluted EPS of $0.03. Adjusted EBITDA was $29.4 million. The company reaffirmed its full-year 2022 guidance for third-party net sales and adjusted EPS.

ZimVie reported a decrease in third-party net sales by (11.5%) on a reported basis and (8.3%) on a constant currency basis compared to Q2 2021. The company's net loss increased to ($8.7) million, and diluted EPS was ($0.33). However, cash and cash equivalents increased to $130.1 million.

ZimVie reported a decrease in third party net sales by 4.6% to $234.7 million. Net loss was ($25.7) million, with a diluted EPS of ($0.98). Adjusted EBITDA was $33.8 million, representing 14.4% of third party sales.